Emtricitabineon offerFactory GMP Emtricitabine98.0%-101.0%(dried substance)  143491-57-0

Lonzeal Pharmaceuticals is drug manufacturer with China/WHO/FDA/ANVISA GMP certificates. We supply pharmaceutical products to esteemed customers globally with high quality, competitive price and good service.

Our Emtricitabine API is in commercial production and has been approved by China NMPA and WHOPQ.

LONZEAL Pharmaceuticals was founded in 2006 and has become a leading manufacturing company covering finished formulation, active pharmaceutical ingredients and advanced intermediates, where ICH guidelines have been strictly applied in the whole chain of R&D, manufacturing process and quality management.

LONZEAL is taking attentiveness and profession to build high quality products, and contributing to health and beautiful life for everyone in the world. The products and manufacturing site of Lonzeal have been approved and inspected by stringent drug authorities such as USFDA, WHO, China NMPA, Brazil ANVISIA and India DCGI, based on which, we have been supplying to esteemed customers globally in the past 15 years with regulatory compliance and good quality.

We have manufacturing site located in Hebei National Biomedical Industrial Zone, FPPs and APIs R&D Center of in Shijiazhuang Hi-tech Development Park, and the commercial office in Beijing, China.

Our current main products cover anti-virus, anti-depression and anti-neuropathic pain areas. Lonzeal has become one of the key manufacturers in the global supply of anti-HIV drugs and is providing support to the treatment need of over 4 Million patients each year worldwide.

Emtricitabine is a new type of nucleoside reverse transcriptase inhibitor successfully developed by GileadSiences of the United States. It is an antiviral drug and has antiviral activity against HIV-1, HIV-2 and HBV. In its specific anti-HIV-1, HIV-2 and HBV, and its drug concentration increased to 100mnol/L, it has not been seen to HSV-1, HSV-2, HCMV, VZV, corona, yellow fever virus, Respiratory syncytial virus, Rota, influenza virus or rhinovirus showed activity. Even if the concentration is lower than micromolar, the drug shows a strong inhibitory effect on the LAV and ⅢB virus strains of HIV1 and the ROD2 and ZY virus strains of HIV-2. Its IC50 value is 95 lower than that of AZT (Zidovudine). Times. 
Whether new anti-HIV drugs will produce cross-resistance to other antiviral drug-resistant virus strains such as AZT has increasingly become the focus of evaluating new drugs. The cross-resistance test of emtricitabine to AZT resistant virus strains showed that although the IC50 value of these resistant strains increased slightly, all virus strains were still relatively sensitive to emtricitabine. The emtricitabine-resistant virus strain will obviously develop cross-resistance to the antiviral drug 3TC (lamivudine), but it is still sensitive to AZT. Studies have shown that the drug can be used in combination with AZT and has a synergistic effect. Emtricitabine exhibits strong antiviral activity in the HBV-producing cell line HepG22.2.15 (PSA subspecies). It can dose-dependently reduce the amount of extracellular and intracellular HBV DNA with an IC50 value of 10nmol/L , This value can be compared with another HBV replication inhibitor 3TC. 
Interferon αnl (Wellferon), α2a (Roferon), α2b (IntronA) can inhibit the production of HBV virus particles and the accumulation of intracellular replication viruses in chronic production cells. They can have a synergistic effect when combined with emtricitabine .